The MTTP inhibitor (lomitapide) is also approved for the treatment of inherited hyperlipidemias like homozygous familial hypercholesterolemia and familial chylomicronemia syndrome, but its usage is associated with severe side effects and therefore is not recommended for the treatment of obesity (Ko et al, 2020). Here, MTTP is linked to obesity disorder.